Leon O. Moulder's most recent trade in Zenas Biopharma Inc. was a trade of 36,928 Common Stock done at an average price of $20.9 . Disclosure was reported to the exchange on Oct. 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 20.85 per share. | 07 Oct 2025 | 36,928 | 36,928 | - | 20.9 | 769,949 | Common Stock |
| Zai Lab ADR | Leon Oliver Moulder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 10,831 | 72,602 (0%) | 0% | 0 | American Depositary Shares | |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Zenas Biopharma Inc | Leon Moulder Oliver | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.67 per share. | 18 Feb 2025 | 25,000 | 266,155 | - | 6.7 | 166,750 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 9.98 per share. | 03 Dec 2024 | 45,000 | 241,155 | - | 10.0 | 449,100 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.76 per share. | 03 Dec 2024 | 25,000 | 196,155 | - | 10.8 | 269,000 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 18 Nov 2024 | 7,500 | 168,655 | - | 15 | 112,500 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 14.57 per share. | 18 Nov 2024 | 2,500 | 171,155 | - | 14.6 | 36,425 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.91 per share. | 18 Sep 2024 | 10,000 | 1,662,039 | - | 17.9 | 179,100 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.89 per share. | 18 Sep 2024 | 5,000 | 1,667,039 | - | 17.9 | 89,450 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 18.97 per share. | 18 Sep 2024 | 2,633 | 1,672,039 | - | 19.0 | 49,948 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.88 per share. | 18 Sep 2024 | 2,367 | 1,669,406 | - | 17.9 | 42,322 | Common Stock |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 3,230,268 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 1,486,000 | 1,486,000 | - | - | Stock Option (Right to Buy) | |
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 1,428,571 | 0 | - | - | Series Seed Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 941,088 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 418,996 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 372,017 | 1,652,039 | - | - | Common Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 164,523 | 1,280,022 | - | - | Common Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 108,381 | 112,901 | - | - | Common Stock | ||
| Zenas Biopharma Inc | Leon Oliver Moulder | Director, Chief Executive Officer | 12 Sep 2024 | 48,254 | 161,155 | - | - | Common Stock | ||
| Zai Lab ADR | Leon O. Moulder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 21,253 | 61,771 (0%) | 0% | 0 | American Depositary Shares | |
| Dianthus Therapeutics Inc | Leon O. Moulder | Director | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | ||
| Dianthus Therapeutics Inc | Leon O. Moulder | Director | 22 Jan 2024 | 166,667 | 1,436,745 | - | 12 | 2,000,004 | Common Stock | |
| Trevena Inc | Leon O. Moulder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 13,700 | 13,700 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Leon O. Moulder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Trevena Inc | Leon O. Moulder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 68,577 | 68,577 | - | - | Stock Option (Right to Buy) |